Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen causing nosocomial infection and is an emerging cause of community-associated infection. Community-associated MRSA (CA-MRSA) has been recognized as a novel pathogen group and has different characteristics from nosocomial MRSA, including limited antibiotic resistance, a different exotoxin gene profile (PantoneValentine leukocidin), a different type of staphylococcal cassette chromosome mec (SCCmec) gene, and a different clinical spectrum. 4, 5 However, CA-MRSA clones vary among different countries and regions. 6e9 In Taiwan, several studies have attempted to compare CA-MRSA and healthcare-associated MRSA (HA-MRSA). Most such studies noted that CA-MRSA strains in Taiwan contain a specific type of the SCCmec VT gene and possess PantoneValentine leukocidin genes. 10e13 However, these studies were mostly limited to a single center, a specific patient group (e.g., children, patients with end-stage renal disease, or adults), or a specific disease pattern (e.g., bacteremia). Additionally, a new community-onset, healthcare-associated MRSA (HA-MRSA-CO) infections have been characterized in patients with community-onset infection who have underlying conditions resulting in frequent exposure to the healthcare system.
14 Previous studies have not thoroughly investigated whether HA-MRSA-CO has characteristics resembling those of CA-MRSA or hospital-onset, healthcare-associated MRSA (HA-MRSA-HO) infection. This study used multicenter surveillance data of clinical MRSA isolates to elucidate the clinical and microbiological characteristics of CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO isolates in Taiwanese patients.
Materials and methods

Study participants
Patients with clinical MRSA isolates were enrolled in the Taiwan Surveillance of Antimicrobial Resistance program IV and V (TSAR IV and V). In 1998, the Division of Clinical Research, National Health Research Institute in Taiwan initiated the TSAR program to survey antimicrobial resistance in Taiwan and to promote national action in controlling antimicrobial resistance. Isolates from inpatients and outpatients of multiple medical centers and regional hospitals across different parts of Taiwan were collected during a 3-month period every 2 years. No duplicate isolates were collected from a single patient. TSAR IV and V were conducted in 2004 and 2006, respectively, at 10 medical centers and 16 regional hospitals in Taiwan.
Variables and definitions
For each patient, the coinvestigator physicians at each study site retrospectively reviewed the charts and recorded data using a standardized data collection form. The data collected included each patient's age, sex, underlying disease, and antimicrobial use (within 2 weeks). The healthcare risk factors for MRSA included a history of MRSA infection or colonization in the year preceding the culture, hospitalization, invasive treatment (dialysis, chemotherapy, or surgery), residence in a long-term care facility or respiratory care ward in the year preceding the culture, and presence of an invasive device at time of admission.
15e17 Additionally, the presence of MRSA infection and the type of infection (as defined by the Centers for Disease Control and Prevention, USA) were defined by primary care physicians and reviewed by infectious disease physicians during chart review. 18 Colonization was defined as having no symptoms or signs of infection at the site of MRSA isolation, and no corresponding anti-MRSA antibiotics were prescribed. The outcome was defined as 30-day allcause mortality and 30-day MRSA-related mortality.
Patients with HA-MRSA-CO had at least one healthcare risk factor and a positive culture obtained within 48 hours of hospital admission. Patients with HA-MRSA-HO had a positive culture obtained 48 hours after hospital admission. CA-MRSA patients had no documented healthcare risk factors and a positive culture obtained within 48 hours of hospital admission.
Bacterial identification
Identification of S. aureus was confirmed by colony morphology on trypticase soy agar supplemented with 5% sheep blood (BBL Microbiology Systems, Cockeysville, MD, USA), Gram stain, catalase test (as needed), and a positive coagulase test (Bactistaph Latex Test; Remel, Lenexa, KS, USA). MRSA strains were identified based on antimicrobial susceptibility testing of all S. aureus isolates (described below).
Susceptibility testing
The minimum inhibitory concentration of 12 antibiotics (chloramphenicol, clindamycin, ciprofloxacin, erythromycin, gentamicin, linezolid, oxacillin, rifampin, teicoplanin, tetracycline, trimethoprim/sulfamethoxazole, and vancomycin) were determined by broth microdilution following the guidelines of the Clinical and Laboratory Standards Institute using custom-designed 96-well panels (Sensititre; Trek Diagnostics, East Essex, England). 19 
DNA extraction
Bacterial DNA was extracted using the InstaGene matrix (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's protocol. Briefly, an isolated bacterial colony was suspended in 1 mL autoclaved water in a microfuge tube and then centrifuged for 1 minute at 6000g. The supernatant was removed, and the InstaGene matrix (200 mL; Bio-Rad) was added to the pellet. The mixture was vortexed, heated at 56 C for 15 minutes, vortexed again, heated at 100 C for 8 minutes, and centrifuged to pellet the matrix. The supernatant was used in subsequent polymerase chain reactions.
Methods for typing the SCCmec element
The presence of SCCmec elements was determined by polymerase chain reaction as previously described. 
Statistical methods
A chi-square test or Fisher's exact test was used to examine the associations of epidemiological variables with SCCmec type, disease spectrum, and antimicrobial susceptibility. A univariate analysis was performed to determine the association between significant variables and mortality among MRSA-infected patients. Variables with a p value <0.2 were included in the multivariate analysis and were assessed using logistic regression. We used STATA statistical software version 9.0 (STATA, College Station, Texas, USA) for analysis.
Results
In this study, five medical centers and four regional hospitals provided clinical isolates from TSAR IV and V programs for 203 patients. There were 69 cases from TSAR IV and 134 cases from TSAR V. Of the 203 patients, 107 were from medical centers and 96 were from regional hospitals.
The percentage of isolates provided by each hospital ranged from 8% to 33%. The general characteristics of these patients are listed in Table 1 . The mean age was 55.6 years with a standard deviation of 26.4 years. The male/female ratio was 138:65. According to the healthcare risk factors and the timing of the cultures, 27 patients were classified as having CA-MRSA (13.3%), 59 as having HA-MRSA-CO (29.1%), and 117 as having HA-MRSA-HO (57.6%). The 30-day all-cause mortality rate was 12.8%. Patients with HA-MRSA-HO isolates had a significantly higher 30-day CA-MRSA Z community-associated methicillin-resistant Staphylococcus aureus; HA-MRSA-CO Z community-onset healthcare-associated MRSA; HA-MRSA-HO Z hospital-onset healthcare-associated MRSA; LTCF Z long-term care facility; RCW Z respiratory care ward.
all-cause mortality rate (20.9%) than patients with CA-MRSA and HA-MRSA-CO infections (7.4% and 0%, respectively; p < 0.001).
Of the 203 patients, 166 patients had MRSA infection; the remaining patients were only colonized. Among the 166 patients with MRSA infection, the most common site of infection was the skin and soft tissues (86/166, 54.1%). The 30-day all-cause mortality rate among these 166 patients was 12.7%, and the MRSA-related 30-day mortality rate was 4.2%. Among these 166 patients, those with HA-MRSA-HO infection had a significantly higher 30-day all-cause mortality rate (20.2%) than those with CA-MRSA and HA-MRSA-CO infections (8.7% and 0%, respectively; p Z 0.002). However, there was no significant difference in MRSArelated 30-day mortality rate among patients with CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO (8.7%, 0%, and 5.3%, respectively; p Z 0.29).
SCCmec typing
The SCCmec type pattern was significantly associated with the epidemiologic classification of the CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO isolates (p < 0.001). Among the CA-MRSA isolates, the most frequent SCCmec type was type VT (40.7%), whereas SCCmec type III was most common in HA-MRSA-CO and HA-MRSA-HO isolates (40.7% and 56.4%, respectively). A significantly higher proportion of HA-MRSA-HO isolates carried SCCmec type II or type III than did CA-MRSA isolates (73.5% vs. 33.3%, p < 0.001) and HA-MRSA-CO isolates (73.5% vs. 47.5%, p Z 0.001). On the other hand, CA-MRSA and HA-MRSA-CO isolates had a significantly higher proportion of type IV, V, and VT than did HA-MRSA-HO (Table 2) .
Antibiotic susceptibility test
All 203 MRSA isolates were susceptible to vancomycin, teicoplanin, and linezolid and had varying levels of susceptibility to other antibiotics. Most MRSA isolates were resistant to erythromycin, clindamycin, and tetracycline (resistance rates of 95.1%, 89.2%, and 75.9%, respectively). HA-MRSA-HO isolates had significantly higher resistant rates to ciprofloxacin, gentamicin, and trimethoprim/sulfamethoxazole compared to CA-MRSA isolates (p < 0.001, p < 0.001, and p Z 0.02, respectively) and HA-MRSA-CO isolates (p Z 0.002, p Z 0.002, and p Z 0.048, respectively). In the subgroup analysis of the HA-MRSA-HO isolates causing infection, there was a significantly higher resistance rate to ciprofloxacin and gentamicin (p < 0.001 and p < 0.001, respectively) and a trend toward a higher resistance rate to trimethoprim/sulfamethoxazole (p Z 0.051) compared with the CA-MRSA isolates causing infection. Compared to the HA-MRSA-CO isolates, the HA-MRSA-HO isolates causing infection also had a significantly higher resistance rate to ciprofloxacin and gentamicin (p Z 0.004 and p Z 0.005, respectively) and a trend toward a higher resistance rate to trimethoprim/sulfamethoxazole (p Z 0.059). There were no significant differences in antibiotic susceptibility between the CA-MRSA and HA-MRSA-CO isolates, regardless of the presence of infection (Table 2) . Table 2 Number and percentage of MRSA isolates by epidemiologic classification, SCCmec typing, and drug susceptibility. 11e13 The present study confirmed these associations across different hospitals in Taiwan. The results were also comparable to those among children in northern Taiwan. 23 Although SCCmec type III was predominant among HA-MRSA cases, 52.5% of HA-MRSA-CO isolates and 26.5% of HA-MRSA-HO isolates carried SCCmec IV, V, or VT in our study. This finding implies that CA-MRSA strains have already spread into the hospitals, resulting in HA-MRSA-HO isolates that carry the classical CA-MRSA SCCmec type. The result is consistent with a previous study of MRSA in Taiwan. 24 Furthermore, the mixed SCCmec typing among HA-MRSA-CO isolates suggested that patients may acquire the infection or colonization from the community, hospital, or other healthcare facility.
On the other hand, previous studies in Taiwan demonstrated that almost all CA-MRSA isolates carry the SCCmec type IV, V, or VT gene. 12, 25, 26 However, 33.3% of CA-MRSA isolates carried SCCmec type III in our study. It is possible that some cases of HA-MRSA were misclassified as CA-MRSA cases due to the retrospective nature of the study. However, we cannot exclude the possibility that the HA-MRSA strains have spread from the hospital setting to the community. This phenomenon must be closely followed and further studied by prospective study setting.
The resistance patterns of CA-MRSA isolates in Taiwan are noteworthy. In the United States, most CA-MRSA strains were reported to be susceptible to erythromycin and clindamycin. 4, 5 In our study, however, the resistance rates to these two antibiotics were universally high among CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO isolates. This was also true among CA-MRSA isolates from children in Taiwan. 27 The high resistance rate to erythromycin may be due to the numerous prescriptions for macrolides in Taiwan, especially in outpatient clinics. 28 The MRSA isolates Table 3 Number and percentage of MRSA isolates leading to clinical infection by epidemiologic classification, genetic classification, and clinical condition.
SCCmec V and VT (n Z 42) carrying SCCmec type IV, V, or VT had high resistance rates to chloramphenicol, clindamycin, erythromycin, and tetracycline (86.2%, 85%, 87.5%, and 68.7%, respectively).
Thus, erythromycin and clindamycin should not be considered for the empiric treatment of suspected CA-MRSA infections in Taiwan. Compared to HA-MRSA-HO isolates, CA-MRSA isolates in Taiwan had lower resistance rates to gentamicin, ciprofloxacin, and trimethoprim/sulfamethoxazole, which may be considered alternatives for the treatment of CA-MRSA infection.
In the present study, there were no significant differences between the CA-MRSA and HA-MRSA-CO isolates with respect to antibiotic resistance rate, mortality rate, SCCmec type, and disease spectrum. Whether the clinical presentation and molecular characteristics of HA-MRSA-CO isolates more closely resembled those of CA-MRSA isolates or HA-MRSA-CO isolates were not extensively studied before. Klevens et al 15 reported a population-based surveillance study of invasive MRSA in the United States and found that the clinical presentation of HA-MRSA-CO isolates resembled that of HA-MRSA-HO isolates. However, their study only included MRSA strains causing invasive infection. Therefore, many isolates from the SSTIs were not included, and the results may not be representative of all MRSA infections. The differences in our results may also be explained by the diversity of HA-MRSA-CO, which may arise from CA-MRSA strains acquired in the community by patients with associated healthcare risks, from HA-MRSA strains acquired in the healthcare setting, or from CA-MRSA strains acquired in the healthcare setting.
The major limitation of this study is information bias due to the retrospective nature of the data collection. Nevertheless, missing data are limited. However, the definition of HA-MRSA established for data collection may have led to misclassifications. Thus, we defined the risk factors for healthcare-associated risk factors as previous MRSA infection or colonization in the year preceding the culture, since it would be difficult to clearly identify previous MRSA infection or colonization that occurred at other hospitals or long before.
In conclusion, beyond nosocomial infection, CA-MRSA strains have become an important component of MRSA colonization and infection acquired in the healthcare setting. They carry different clinical presentations and molecular characteristics from the traditional HA-MRSA strains. MRSA strains are spreading between the community and hospitals, leading to mixed SCCmec types. Furthermore, the antibiotic resistance pattern is becoming more difficult to predict, which may complicate the selection of empiric antibiotics for the treatment of MRSA infections in the future.
